MetaVia Inc - Company Profile
Powered by 
All the sales intelligence you need on MetaVia Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how MetaVia Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with MetaVia Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
MetaVia Inc (MetaVia ), a subsidiary of Dong-A ST Co Ltd, develops and commercializes pharmaceuticals targeting cardiometabolic diseases. The company focuses on creating innovative therapies for conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and obesity. MetaVia's key programs include DA-1241, a G-Protein-Coupled Receptor 119 agonist, and DA-1726, an oxyntomodulin analogue. The company operates within the biotechnology and pharmaceutical industries, concentrating on research and development activities, preclinical developments, and clinical trials.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
MetaVia’s R&D initiatives focus on developing innovative therapies for cardiometabolic diseases. The company is advancing two key assets: DA-1241, a GPR119 agonist in Phase 2a trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and DA-1726, a GLP-1 receptor and glucagon receptor dual agonist in Phase 1 trials for obesity. DA-1241 has shown potential in reducing hepatic steatosis, inflammation, and fibrosis, while DA-1726 aims to induce weight loss and improve body composition. MetaVia Inc is also exploring the efficacy of DA-1241 in combination with sitagliptin, a DPP-4 inhibitor, to enhance therapeutic outcomes. Its R&D unit is responsible for managing the company's research and development activities, including preclinical developments, clinical trials, and the advancement of product candidates through various phases of clinical development. The unit focuses on identifying, recruiting, retaining, and integrating qualified scientific personnel to support these initiatives. In FY2024, the company invested US$21.5 million, which grew 135.4% YoY.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer